|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The modification of this translocation may lead to reducing effects of the fusion gene's damaging and the dosage compensation related to ETV6 and RUNX1 genes and subsequently reduce the effects of leukemia.
|
31602594 |
2020 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
WW domain binding protein 1-like (WBP1L), also known as outcome predictor of acute leukaemia 1 (OPAL1), is a transmembrane adaptor protein, expression of which correlates with ETV6-RUNX1 (t(12;21)(p13;q22)) translocation and favourable prognosis in childhood leukaemia.
|
31845480 |
2020 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that germline aberrations resulting in monoallelic expression of <i>ETV6</i> contribute to leukemia susceptibility, whereas more severe functional deficiency of ETV6 is required for developing THC5.
|
31519648 |
2019 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Care for individuals with ETV6-related thrombocytopenia and leukemia predisposition includes genetic counseling, treatment or prevention of excessive bleeding and surveillance for the development of hematologic malignancy.
|
31248877 |
2019 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 4-log-stage linearity of R2 ≥ 99.81% and a sensitivity of one leukemia associated ETV6-RUNX1 mutant DNA copy in a background of 100 000 wild-type DNA copies are achieved.
|
31139783 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, this study identifies SPIB as an important target of ETV6-RUNX1 in regulation of B-cell gene expression in t(12;21) leukemia.
|
30986496 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CRKL is tightly linked to leukemia via its binding partners BCR-ABL and TEL-ABL, upregulated in multiple types of human cancers, and induce cancer cell proliferation and invasion.
|
31133010 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Second, in a small fraction of these cases, the postnatal acquisition of secondary genetic changes (primarily V(D)J recombination-activating protein (RAG) and activation-induced cytidine deaminase (AID)-driven copy number alterations in the case of ETS translocation variant 6 (ETV6)-runt-related transcription factor 1 (RUNX1)<sup>+</sup> ALL) drives conversion to overt leukaemia.
|
29784935 |
2018 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Future researches are needed to explain how ETV6 mutations act within the microenvironment of leukemic cells and how it affects the progression of leukaemia.
|
29894279 |
2018 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prenatal origin of the rearrangement confirms that ETV6-ABL1 is not sufficient to cause overt leukemia, even when combined with the 2 novel fusions.
|
29726059 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletions affecting the transcriptional coregulator BTG1 are frequently observed in ETV6-RUNX1-positive leukemia.
|
29408281 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanism of ETV6-RUNX1 Leukemia.
|
28299659 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As with ABL, translocations that fuse ARG to ETV6/TEL have been identified in patients with leukemia.
|
28386107 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest ETV6-RUNX1 is associated with space-time clustering of CL and are consistent with an infection interacting with that oncogene in early life leading to clinical leukemia.
|
28129329 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the ETV6-RUNX1 fusion was found to encode putative neoepitopes in a high proportion (69.6%) of the pediatric leukemia harboring this fusion.
|
28854978 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ETV6 in hematopoiesis and leukemia predisposition.
|
28637624 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most frequent chromosomal changes in subgroups divided according to WHO classification independent of treatment protocol and leukemia subtype were hyperdiploidy in 36 patients (with ≥50 chromosomes in 23 patients, with 47-49 chromosomes 13 patients) followed by translocation t(12;21) with ETV6/RUNX1 fusion detected by FISH in 18 (22%) patients.
|
27341996 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As few <i>ETV6-RUNX1</i> carriers develop precursor B-cell acute lymphocytic leukemia (pB-ALL), the underlying genetic basis for development of full-blown leukemia remains to be identified, but the appearance of leukemia cases in time-space clusters keeps infection as a potential causal factor.
|
28630052 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We provide mechanistic support for the concept that altered patterns of infection during early childhood can deliver the necessary promotional drive for the progression of ETV6-RUNX1+ pre-leukaemic cells into a postnatal overt leukaemia.
|
28299660 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
|
28650474 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secondary chromosomal aberrations are necessary for development of overt leukemia in t(12;21)/ETV6-RUNX1-positive acute lymphoblastic leukemia (ALL).
|
27215399 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show here for the first time that LPXN is a fusion partner of ETV6 and present evidence indicating that ETV6-LPXN plays a crucial role in leukemia progression through enhancing the response to G-CSF and CXCL12.
|
26542893 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of leukemias with ETV6-ABL1 fusion.
|
27229714 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All together, our study defined a unique lncRNA expression signature associated with ETV6/RUNX1-positive BCP-ALL and identified lnc-RTN4R-1 and lnc-NKX2-3-1 as lncRNAs that might be functionally implicated in the biology of this prevalent subtype of human leukemia.
|
27650541 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetically, CD200/BTLA deletions were strongly associated with ETV6-RUNX1-positive leukemias (P<0.0001), but were also identified in patients who did not have any genetic abnormality that is currently used for risk stratification.
|
26137961 |
2015 |